Thoracic (Lung/chest)

AZ TRITON – D419NL00003 at http://clinicaltrials.gov/study/NCT06008093

A Phase IIIb, Randomized, Multicenter, Open-Label Study to assess the Efficacy of Durvalumab plus Tremelimumab verus Chemotherapy for First-Line Treatment in Metastatic Non-Small Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1 or KRAS

Cancer Type: NSCLC, Stage IV, Non-Squamous and Squamous